illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Photocure
Company logo

Photocure | Sustainability Performance

https://www.photocure.com
Linkedin

Photocure is engaged in pharmaceutical development, with a focus on products for the treatment of bladder cancer. The company aims to advance patient care through innovative therapies while emphasizing safety and efficacy in its product offerings.

1993

Norway

51 - 200 employees

Pharmaceuticals

$25M - 100M in revenue

$0 - 100K in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#8152
Overall
#159
in Norway
#191
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and exclusions
Financial Data
Business performanceCapital & innovation

View similiar companies


Company logo
Circio

Norway, Hospital & Health Care, Biotechnology


Company logo
Exact Therapeutics

Norway, Hospital & Health Care, Biotechnology


Company logo
Navamedic

Norway, Hospital & Health Care, Pharmaceuticals

Market cap

112.7M $, 2026▼28.2% YoY

Revenue

51.4M $, 2026

R&D intensity

0% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Photocure's marketing of Hexvix for bladder cancer detection was scrutinized for claims about diagnostic accuracy improvements.
Powered by illuminem

Market cap

112.7M $, 2026▼28.2% YoY

Revenue

51.4M $, FY2026▼NaN% YoY

EBITDA

90.0K $, FY2026▼9.1% YoY

Operating margin

0% Industry: -631▲3310.5% YoY

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

6.3M 2024▲44.9% YoY

Capex

1.1M 2024▼9.1% YoY

Debt/equity ratio

0.2 Industry: 0▼NaN% YoY

R&D intensity

0.0%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

0.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

15%
Independent Directors

2 out of 13 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

image report
Available

Sustainability employees


Total sustainability employees

2-3


    Available in
    Scale package

    Access
  • Email

  • Email